rawfin.tv
Johnson & Johnson's TREMFYA Shows Efficacy in Spinal Pain Study
MarketsstocksAI Generated

Johnson & Johnson's TREMFYA Shows Efficacy in Spinal Pain Study

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Johnson & Johnson announced positive Phase 4 clinical trial results for its drug TREMFYA (guselkumab), which met primary and major secondary endpoints. The study, involving 411 participants, demonstrated improvement in spinal pain and stiffness.

pharmaceuticalsclinical-trialsdrug-developmenthealthcare-sectorJ&J

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks